Form 8-K Apellis Pharmaceuticals, For: Jul 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Apellis Pharmaceuticals (APLS) extends yesterday's decline, down another 13% on SYFOVRE concerns
July 18, 2023 9:51 AM EDT(Updated - July 18, 2023 10:24 AM EDT)
Apellis Pharmaceuticals (NASDAQ: APLS) extends yesterday's decline, down another 13%
After the close of trading on Monday, it confirmed reports of six events of retinal vasculitis following SYFOVRE treatment. The issue had weighed on shares during the regular session.From the filing:
Apellis Pharmaceuticals, Inc. (the Company) has received reports of six events of retinal vasculitis following SYFOVRE® (pegcetacoplan injection) treatment. The Company has... More
KOL thinks Apellis Pharmaceuticals (APLS) issues with Syfovre 'likely solvable' - TD Cowen
July 17, 2023 4:22 PM EDTTD Cowen analyst Phil Nadeau weighed in on Apellis Pharmaceuticals (NASDAQ: APLS) after shares fell 38% after six cases of retinal vasculitis have been reported with Syfovre.
The analyst commented, "During TD Cowen Rounds @ Cleveland Clinic today we discussed the situation with a... More
